Condition deep-dive · 6 min read

Psoriatic arthritis adjunct — what supplements actually have evidence

Updated 2026-05-21 · Reviewed by SupplementScore editors · No sponsorships

Psoriatic arthritis sits at the intersection of inflammatory arthritis, psoriasis, and the metabolic-syndrome cluster (obesity, dyslipidaemia, insulin resistance, NAFLD). The medical backbone — NSAIDs for symptom control, csDMARDs like methotrexate, and biologics targeting TNF, IL-17, IL-23 — is rheumatology-led. The supplement adjunct framework reflects the disease's three pillars: an anti-inflammatory layer (omega-3, vitamin D), a metabolic-syndrome layer (the same supplements that help insulin resistance and dyslipidaemia), and avoidance of immune-stimulating compounds that can flare psoriasis.

Read this first. Methotrexate, the most common DMARD in PsA, has well-characterised interactions: avoid high-dose folic acid in users on methotrexate (low-dose folic acid 1 mg/day is part of standard practice; very high doses theoretically reduce methotrexate efficacy). NSAIDs add bleeding risk to fish oil at very high doses. Echinacea, Astragalus, and other immune-stimulating supplements can theoretically flare psoriasis. Drug interactions with biologics are largely theoretical at supplemental doses but should be discussed with the prescribing rheumatologist.

What actually works in trials

Tier 1 evidence · The most important adjunct layer

Omega-3 EPA/DHA (high dose)

2–3 g/day combined EPA+DHA, taken with food

RCTs in psoriasis and PsA have shown reductions in joint counts, morning stiffness, and inflammatory markers with high-dose omega-3 over 12–24 weeks. The cardiovascular argument is independently strong — PsA carries a meaningful excess CV event risk that omega-3 addresses alongside lipid management.

Tier 1 evidence · Vitamin status and immune modulation

Vitamin D3 (to 25-OH-D 40–60 ng/mL target)

2,000–4,000 IU/day adjusted by 25-OH-D testing

Low vitamin D status is common in PsA and psoriasis cohorts and correlates with disease activity. Supplementation in deficient patients improves both skin and joint metrics in small trials. Vitamin D is also important for bone health in users on corticosteroids.

Tier 2 evidence · Anti-inflammatory adjunct

Curcumin (bioavailable form)

500–1000 mg/day of Meriva, BCM-95, or equivalent phytosome form

Small RCTs in psoriasis and PsA have shown reductions in PASI scores and inflammatory markers with bioavailable curcumin. Standard turmeric powder has trivial systemic bioavailability; phytosome and BCM-95 forms have 10–20× higher absorption. Watch for additive antiplatelet effects with NSAIDs.

Tier 2 evidence · Metabolic-syndrome adjunct

Berberine (in insulin-resistant PsA patients)

500 mg twice daily with meals

Insulin resistance, NAFLD, and prediabetes are part of the PsA syndrome in many patients. Berberine has trial-level evidence on insulin sensitivity, lipid panel, and HbA1c. Coordinate with the prescriber if on metformin (additive effect) or any liver-metabolised medication.

Tier 2 evidence · Standard adjunct in methotrexate use

Folic acid (low-dose, methotrexate co-supplementation)

1 mg/day folic acid; some regimens use 5 mg weekly

Folate supplementation is standard with methotrexate to reduce GI and hepatic side effects without meaningfully reducing efficacy. Use the dose your rheumatologist prescribes; high-dose self-supplementation is not appropriate.

What to skip

What to track

Standard PsA monitoring: tender/swollen joint counts, PASI for skin involvement, DAS28-CRP or similar composite, CRP, ESR. Add 25-OH-D at baseline and at 8–12 weeks of vitamin D supplementation. Lipid panel and metabolic panel given the metabolic-syndrome context. For trials of curcumin or omega-3 expect 12 weeks before judging effect. Watch for liver enzyme changes if on methotrexate plus any liver-metabolised supplement.

Practical quick-start. Confirm rheumatology-led plan (DMARDs/biologics, NSAID strategy). Test 25-OH-D and supplement vitamin D3 to 40–60 ng/mL. Add omega-3 2–3 g/day combined EPA+DHA. If metabolic syndrome is part of the picture, add berberine 500 mg b.i.d. with prescriber awareness. Bioavailable curcumin at 500–1000 mg/day is reasonable as an anti-inflammatory layer. Reassess at 12 weeks.

Educational reference, not medical advice. PsA management is rheumatology-led; coordinate any supplement use with the prescribing team, particularly for users on methotrexate, biologics, or NSAIDs.

Sources

Read more: